What’s Driving the 7.8% Revenue Growth in India’s Pharma Market for April?
Click to start listening
Synopsis
India's pharmaceutical sector is booming! With a remarkable <b>7.8% year-on-year revenue growth</b> in April, the market is driven by strategic price hikes and innovative product launches. Explore how chronic therapies and anti-diabetic segments are leading this growth trend.
Key Takeaways
- 7.8% yoy revenue growth in India’s pharmaceutical market for April.
- Price increases and new product launches are key drivers.
- Chronic therapies continue to show strong growth momentum.
- Volume growth was notable in anti-diabetic and gastro-intestinal therapies.
- Overall, a positive outlook for FY26 with expected growth of 7-8%.
New Delhi, May 8 (NationPress) The pharmaceutical market in India (IPM) has recorded a robust growth of 7.8 percent year-on-year (yoy) in revenue for April, as reported on Thursday.
This report, published by the rating agency India Ratings and Research (Ind-Ra), indicates that the growth was primarily fueled by price increases implemented by companies, with a 1.3 percent yoy growth in volume. Notably, the majority of major chronic therapies also exhibited positive growth in both value and volume.
“Ind-Ra anticipates the IPM to achieve a growth rate of 7 percent to 8 percent yoy during FY26, supported by a consistent growth trend in chronic therapies, driven by price hikes and new product introductions,” stated Nishith Sanghvi, Director of Corporate Ratings at Ind-Ra.
The report detailed that the anti-diabetic sector witnessed a volume growth of 2.8 percent yoy in April, attributed to opportunities from genericization.
Additionally, significant volume growth was recorded in key therapy areas including gastro-intestinal (5.5 percent), dermatology (3.1 percent), and cardiac (2.2 percent).
Moreover, April 2025 showed a stable performance with value growth noted across various therapies.
Therapies such as cardiac, gastro-intestinal, anti-diabetic, and dermatology experienced higher volume growth compared to the overall IPM.
Acute therapies, including gastro-intestinal, vitamins, pain/analgesics, and anti-infectives, saw sales growth of 10.1 percent, 7.5 percent, 8.5 percent, and 6.5 percent yoy respectively.
Chronic therapies like dermatology, cardiac, anti-diabetic, and CNS grew 10.8 percent yoy, 10.6 percent yoy, 7.7 percent yoy, and 9.1 percent yoy correspondingly.
The March report from Ind-Ra indicated that the acute segment's sales grew 6.4 percent yoy (March 2024: 6.7 percent yoy), while chronic and sub-chronic therapy segments rose by 8.0 percent yoy (12.8 percent) and 8.4 percent yoy (12.3 percent) respectively.
Cardiac (chronic; 13.4 percent of IPM), anti-infectives (acute; 11.7 percent), gastro-intestinal (acute; 12.1 percent), anti-diabetic (chronic; 9.2 percent), and vitamins (acute; 9.0 percent) collectively contributed 55 percent to the IPM in March 2025.
Point of View
I see the growth in India's pharmaceutical market as a sign of resilience and innovation. The 7.8% revenue growth is a reflection of the sector's adaptability and commitment to meeting healthcare needs. This sustained momentum in chronic therapies not only underpins the market's potential but also highlights the importance of affordable healthcare solutions for the nation.
NationPress
08/05/2025
Frequently Asked Questions
What factors contributed to the growth of the Indian pharma market?
The growth was driven mainly by price hikes implemented by companies and a consistent volume increase in chronic therapies, particularly in anti-diabetic and gastro-intestinal segments.
What is the expected growth rate for the Indian pharma market in FY26?
India Ratings and Research (Ind-Ra) anticipates the Indian pharmaceutical market to grow between 7 percent and 8 percent year-on-year during FY26.
Which therapy segments are leading in volume growth?
Key therapy segments leading in volume growth include gastro-intestinal, dermatology, cardiac, and anti-diabetic therapies.
